Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2018

  • ID: 4599978
  • Drug Pipelines
  • 90 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acacia Pharma Ltd
  • Athenex Inc
  • IntelGenx Corp
  • MannKind Corp
  • N4 Pharma Plc
  • Pivot Pharmaceuticals Inc
  • MORE
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2018, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights:

This latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 5, 5, 1, 1, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acacia Pharma Ltd
  • Athenex Inc
  • IntelGenx Corp
  • MannKind Corp
  • N4 Pharma Plc
  • Pivot Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Chemotherapy Induced Nausea and Vomiting - Overview

Chemotherapy Induced Nausea and Vomiting - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development

Acacia Pharma Ltd

Aphios Corp

Athenex Inc

Camurus AB

Daewoong Pharmaceutical Co Ltd

Hoverink Biotechnologies Inc

IntelGenx Corp

Kyowa Hakko Kirin Co Ltd

MannKind Corp

Medlab Clinical Ltd

N4 Pharma Plc

Nemus Bioscience Inc

Pivot Pharmaceuticals Inc

Serina Therapeutics Inc

SoluBest Ltd

Suda Pharmaceuticals Ltd

Chemotherapy Induced Nausea and Vomiting - Drug Profiles

(netupitant + palonosetron hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cannabis CINV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosnetupitant chloride hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPI-1504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPI-1505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-1940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netupitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olanzapine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palonosetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palonosetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize CB1 and CB2 for Chemotherapy Induced Nausea and Vomiting - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chemotherapy Induced Nausea and Vomiting - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zindol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Nausea and Vomiting - Dormant Projects

Chemotherapy Induced Nausea and Vomiting - Discontinued Products

Chemotherapy Induced Nausea and Vomiting - Product Development Milestones

Featured News & Press Releases

Jul 09, 2018: Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Jul 03, 2018: Ministry approves CJ Healthcare’s CINV treatment

Jun 28, 2018: Helsinn Therapeutics (U.S.) becomes the Exclusive Distributor of ALOXI (palonosetron HCI) in the US

May 18, 2018: Helsinn Group and Mundipharma announce the launch of AKYNZEO hard capsule for oral use in Brazil

May 15, 2018: AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco

Apr 24, 2018: Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018

Apr 20, 2018: Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO (fosnetupitant/palonosetron) in the United States

Jan 17, 2018: US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi in the US Market Are Invalid

Dec 22, 2017: N4 Pharma: Filing of Patent

Dec 12, 2017: AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission

Nov 28, 2017: New single capsule treatment AKYNZEO now available for the prevention of chemotherapy-induced nausea and vomiting in Canada

Jun 20, 2017: Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC

May 15, 2017: AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on NIH Website

May 03, 2017: Patent Infringement Litigation For Antiemetic Agent ALOXI In The United States

May 02, 2017: Helsinn Healthcare vs. Teva Pharmaceuticals on Aloxi patent for the US market

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex Inc, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Hoverink Biotechnologies Inc, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by IntelGenx Corp, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by N4 Pharma Plc, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Pivot Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H2 2018

Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Pharmaceuticals Ltd, H2 2018

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2018

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2018 (Contd..1), H2 2018

Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acacia Pharma Ltd
  • Aphios Corp
  • Athenex Inc
  • Camurus AB
  • Daewoong Pharmaceutical Co Ltd
  • Hoverink Biotechnologies Inc
  • IntelGenx Corp
  • Kyowa Hakko Kirin Co Ltd
  • MannKind Corp
  • Medlab Clinical Ltd
  • N4 Pharma Plc
  • Nemus Bioscience Inc
  • Pivot Pharmaceuticals Inc
  • Serina Therapeutics Inc
  • SoluBest Ltd
  • Suda Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll